Scientists in China have announced a major medical breakthrough that could significantly change the future of diabetes treatment worldwide.
Researchers say they have developed a stem cell–based therapy capable of restoring the body’s ability to produce insulin, offering new hope for people living with both Type 1 and Type 2 diabetes.
According to the research team, the treatment involves using stem cells to regenerate insulin-producing pancreatic cells that are either damaged or destroyed in people with diabetes.
Read also: Chief Imam Condemns Donald Trump For Eliminating Iran Supreme Leader
In Type 1 diabetes, the body’s immune system attacks and destroys these insulin-producing cells, while in Type 2 diabetes the body becomes resistant to insulin or produces insufficient amounts of it.
The scientists reported that their experimental therapy successfully stimulated the regeneration of these critical cells, allowing the body to begin producing insulin naturally again.
If further research confirms these findings, the therapy could reduce or even eliminate the need for daily insulin injections for millions of people around the world.
Although the results are promising, medical experts caution that the treatment is still undergoing research and clinical testing.
Large-scale trials will be required to confirm its long-term safety, effectiveness, and accessibility before it can be widely adopted in hospitals and clinics.
Diabetes remains one of the most widespread chronic diseases globally, affecting hundreds of millions of people and placing a significant burden on healthcare systems.
A reliable treatment capable of restoring natural insulin production could represent one of the most important advances in modern medicine.
Also read: Mansoureh Khojasteh Bagherzadeh, Wife of Iran’s Supreme Leader, Dies After Airstrike Injuries
Health researchers around the world are closely monitoring the development, which many believe could mark a turning point in the global fight against diabetes if the therapy proves successful in broader clinical trials.